Catalyst Wire Dossier Catalyst Wire Dossier

PLD-cyclophosphamide-Nab-P

pegylated liposomal doxorubicin + cyclophosphamide + nab-paclitaxel
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for PLD-cyclophosphamide-Nab-P, covering 2022-04-26 to 2022-04-26. Get the full timeline:

Most recent: Clinical Trial Update: PLD-cyclophosphamide-Nab-P Continuously Combined With Dual HER2 Blockage for HER2-positive Breast Cancer [Phase 2]

See pricing